2-[5-(4-Methoxy-phenyl)-2H-[1,2,3]triazol-4-yl]-pyridine | 710946-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[5-(4-Methoxy-phenyl)-2H-[1,2,3]triazol-4-yl]-pyridine
• 英文别名: 2-[5-(4-methoxyphenyl)-2H-triazol-4-yl]pyridine
• CAS: 710946-95-5
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: DAEHOFBWCCHRTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[5-(4-Methoxy-phenyl)-2H-[1,2,3]triazol-4-yl]-pyridine 在 sodium hydroxide 、 双氧水 、 四丁基碘化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 4.0h， 生成 4-[4-(4-Methoxy-phenyl)-5-pyridin-2-yl-[1,2,3]triazol-2-ylmethyl]-benzamide
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024
• 作为产物：
  描述：

  2-[2-(4-甲氧基苯基)乙炔基]吡啶 在 叠氮基三甲基硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 以38%的产率得到2-[5-(4-Methoxy-phenyl)-2H-[1,2,3]triazol-4-yl]-pyridine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024

文献信息

• Macrocyclic hepatitis C serine protease inhibitors
  申请人：Miao Zhenwei

  公开号：US20050153877A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I、II或III的化合物，或其药用可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过给主体投药包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Miao Zhenwei

  公开号：US20090304629A1

  公开（公告）日：2009-12-10

  The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及I、II或III式化合物，或其药学上可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物能够抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包括上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予包括本发明的化合物的制药组合物来治疗受试者的HCV感染的方法。
• EP1590442A4
  申请人：——

  公开号：EP1590442A4

  公开（公告）日：2007-07-18
• US7601709B2
  申请人：——

  公开号：US7601709B2

  公开（公告）日：2009-10-13
• US8124584B2
  申请人：——

  公开号：US8124584B2

  公开（公告）日：2012-02-28